![Corleen Roche](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Corleen Roche
Directeur Financier/CFO chez
IOVANCE BIOTHERAPEUTICS, INC.
Fortune : 567 959 $ au 30/09/2026
Profil
Corleen M.
Roche is currently Chief Financial Officer at Iovance Biotherapeutics, Inc. since 2025.
Formerly, Ms. Roche was Secretary, Chief Financial & Accounting Officer at CG Oncology, Inc. from 2024 to 2025; Chief Financial & Accounting Officer at Immunome, Inc. from 2021 to 2024; Chief Financial Officer at Biogen, Inc. from 2019 to 2021; Chief Financial Officer at Sandoz, Inc. from 2015 to 2019.
Ms. Roche also held Chief Financial Officer roles at Iogenetics LLC, CSL Behring LLC, Wyeth Pharmaceuticals, Inc., and Pfizer Inc. Ms. Roche completed undergraduate education at Villanova University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 06/08/2026 | 28 757 ( 0,01 % ) | 426 179 $ | 30/09/2026 | |
| 01/03/2026 | 2 000 ( 0 % ) | 141 780 $ | 30/09/2026 |
Postes actifs de Corleen Roche
| Sociétés | Poste | Début |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Directeur Financier/CFO | 06/08/2025 |
Anciens postes connus de Corleen Roche
| Sociétés | Poste | Fin |
|---|---|---|
| CG ONCOLOGY, INC. | Directeur Financier/CFO | 05/08/2025 |
| IMMUNOME, INC. | Directeur Financier/CFO | 02/01/2024 |
| BIOGEN INC. | Directeur Financier/CFO | 01/04/2021 |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes generic pharmaceutical products | Directeur Financier/CFO | 01/01/2019 |
CSL Behring LLC
 CSL Behring LLC BiotechnologyHealth Technology Manufactures and markets plasma protein products | Directeur Financier/CFO | - |
Formation de Corleen Roche
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
62
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes generic pharmaceutical products | Health Technology |
Immunome, Inc.
 Immunome, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which discovers, develops and commercializes antibody therapeutics | Health Technology |
Iogenetics LLC
 Iogenetics LLC Miscellaneous Commercial ServicesCommercial Services Develops proprietary antimicrobial proteins and immunogenetics solutions | Commercial Services |
Villanova University
 Villanova University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology Manufactures and markets plasma protein products | Health Technology |
Iovance Biotherapeutics, Inc.
 Iovance Biotherapeutics, Inc. BiotechnologyHealth Technology Develops biotechnological products for the treatment of cancer | Health Technology |
CG Oncology, Inc.
 CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
Wyeth Pharmaceuticals, Inc.
 Wyeth Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
